Abstract
The Bayer‐activities of daily living (B‐ADL) is a brief and internationally applicable ADL instrument which has been validated in three European countries. The B‐ADL has been developed to provide a tool for the assessment of functional deficits in performance of every day tasks as they are observed in mild to moderate stages of dementia. The B‐ADL has been constructed for use in clinical trials as well as in clinical practice. From an international perspective the major application is the evaluation of treatment effects in clinical studies and the current study was to validate the Korean version of the B‐ADL. The B‐ADL was administered to a total of 129 subjects with varying degrees of cognitive decline. A substantial cross‐sectional correlation between B‐ADL and MMSE scores was found. The internal consistency of B‐ADL was above 0.98. A factor analysis revealed that a one factor solution accounted for most of the total variance. The B‐ADL global score significantly increased as the severity of dementia, assessed by global deterioration scale increased from stage 1 to 5. Test–retest reliabilities of B‐ADL global score and each item were very high. All of these results were very similar to those from three European countries except for the proportion of ‘non‐applicability’ in some ADL items. These findings provide evidence that the Korean version of B‐ADL can be useful not only for clinical purposes but also for international multicentre studies. Copyright © 2003 John Wiley & Sons, Ltd.